FR2686087B1 - - Google Patents

Info

Publication number
FR2686087B1
FR2686087B1 FR9200255A FR9200255A FR2686087B1 FR 2686087 B1 FR2686087 B1 FR 2686087B1 FR 9200255 A FR9200255 A FR 9200255A FR 9200255 A FR9200255 A FR 9200255A FR 2686087 B1 FR2686087 B1 FR 2686087B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9200255A
Other languages
French (fr)
Other versions
FR2686087A1 (fr
Inventor
Boumsell
Bensussan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR9200255A priority Critical patent/FR2686087A1/fr
Priority to PCT/FR1993/000025 priority patent/WO1993014125A1/fr
Publication of FR2686087A1 publication Critical patent/FR2686087A1/fr
Application granted granted Critical
Publication of FR2686087B1 publication Critical patent/FR2686087B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR9200255A 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. Granted FR2686087A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
PCT/FR1993/000025 WO1993014125A1 (fr) 1992-01-13 1993-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9200255A FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Publications (2)

Publication Number Publication Date
FR2686087A1 FR2686087A1 (fr) 1993-07-16
FR2686087B1 true FR2686087B1 (ru) 1994-04-22

Family

ID=9425559

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9200255A Granted FR2686087A1 (fr) 1992-01-13 1992-01-13 Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.

Country Status (2)

Country Link
FR (1) FR2686087A1 (ru)
WO (1) WO1993014125A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) * 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
PL3002298T3 (pl) 2007-11-21 2020-03-31 Oregon Health & Science University Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania
SI2370466T1 (sl) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
MX353476B (es) 2010-09-02 2018-01-15 Vaccinex Inc Star Anticuerpos anti-cxcl13 y metodos para usarlos.
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
CN110105452A (zh) 2011-10-11 2019-08-09 瓦西尼斯公司 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途
AU2012332814B2 (en) 2011-11-02 2017-12-14 Biogen International Neuroscience Gmbh Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
WO2014137355A1 (en) 2013-03-08 2014-09-12 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
AU2014302812B2 (en) 2013-06-25 2019-07-11 Vaccinex, Inc. Use of semaphorin-4D inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MY190209A (en) 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
AU2017354743A1 (en) 2016-11-07 2019-06-06 DegenRx B.V Novel amyloid beta oligomer specific binding molecule
JP7159187B2 (ja) 2017-03-20 2022-10-24 バクシネックス インコーポレーティッド セマフォリン－４ｄ抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102614472B1 (ko) 2019-03-28 2023-12-14 백시넥스 인코포레이티드 암 요법에 사용하기 위한 세마포린-4d 길항제
JP2022537453A (ja) 2019-06-21 2022-08-25 バクシネックス インコーポレーティッド セマフォリン４ｄ遮断（ｓｅｍａ４ｄ）とｄｃ１療法との併用療法
CA3152371A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
BR112022026426A2 (pt) 2020-06-25 2023-04-18 Vaccinex Inc Uso de moléculas de ligação à semaforina-4d para o tratamento de síndrome de rett
WO2023048726A1 (en) 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
WO2023154906A1 (en) 2022-02-13 2023-08-17 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942579A1 (de) * 1989-12-22 1991-06-27 Basf Ag Neue proteine

Also Published As

Publication number Publication date
FR2686087A1 (fr) 1993-07-16
WO1993014125A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
FR2686087B1 (ru)
TW238351B (ru)
DE9200239U1 (ru)
DE9200066U1 (ru)
DE9214821U1 (ru)
DE9200060U1 (ru)
DE9200245U1 (ru)
DE9200047U1 (ru)
DE9200311U1 (ru)
DE9200287U1 (ru)
BR9202713C1 (ru)
DE9200163U1 (ru)
DE9200099U1 (ru)
DE9200290U1 (ru)
DE9200108U1 (ru)
DE9200182U1 (ru)
DE9206953U1 (ru)
DE9200087U1 (ru)
DE9200322U1 (ru)
DE9200325U1 (ru)
TW235263B (ru)
DE9200106U1 (ru)
DE9200292U1 (ru)
BRPI9204323A2 (ru)
DE9200048U1 (ru)

Legal Events

Date Code Title Description
ST Notification of lapse